{"success":true,"data":{"pressRelease":{"id":"169776","rtpr_id":"nPn2lHSTwa-20261015","ticker":"EVO","exchange":"NASDAQ","all_tickers":["EVO","EVTG"],"title":"Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board","author":"PR Newswire","published_at":"2026-10-15T06:05:07.337Z","article_body":"Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board\nPR Newswire\n\nHAMBURG, Germany, Oct. 15, 2026\n\n * Will lead Evotec's global scientific strategy and drive differentiation across\nits discovery and development services, technology platforms and proprietary\ninnovation\n * Brings more than 25 years of global experience in pharma, biotechnology and\nacademia\nHAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO)\n(Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna\nHolbrook as Chief Scientific Officer and Member of the Management Board,\neffective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years\nof experience as both a scientist and R&D leader, applying novel\ntechnologies and data approaches to the challenges of drug discovery and\nadvancing programs toward the clinic. Her experience spans multi-modal 'omics,\ndata science, novel therapeutic modalities and precision medicine,\ncomplemented by experience in commercializing innovative technologies, shaping\ndrug discovery partnerships and leading therapeutic research portfolios. At\nEvotec, Dr. Holbrook will draw on recent scientific advances to help customers\nand partners discover and develop new medicines faster and with a higher\nprobability of success.\n\nDr. Christian Wojczewski, Chief Executive Officer of Evotec, said:\n\n\"Joanna has a keen understanding of how data, AI and new technologies are\ntransforming drug discovery and development today. She combines this\nforward-looking perspective with deep scientific expertise and a strong focus\non generating robust, actionable results. I look forward to working with her\nas we continue to strengthen Evotec's position as a leading partner for any\norganization that strives to bring new, groundbreaking medicines to market.\"\n\nDr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal\nand Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk.\nPrior to that she held positions at UK biotech companies Biomodal, where she\nserved as Chief Scientific Officer, and BenevolentAI, where she was Vice\nPresident, Translational Medicine. She was also Professor of Bioinformatics at\nthe University of Southampton and Senior Principal Investigator at the\nSingapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at\nNational University of Singapore. She started her career at GSK, where she\nheld positions of increasing responsibility across therapy areas and\nbioinformatics. She holds a Ph.D. in Molecular Cell Biology from University\nCollege London and a B.Sc. in Genetics from the University of Newcastle.\n\nDr. Joanna Holbrook, Evotec's incoming Chief Scientific Officer, added:\n\n\"Evotec has exceptional breadth of scientific expertise and capabilities\nspanning drug discovery, drug development and manufacturing. I am excited by\nthe opportunity to work across the business to strengthen our scientific\ndifferentiation, build integrated solutions to the most important challenges\nin drug discovery, and develop new capabilities that are unique to Evotec.\"\n\nAbout Evotec SE\n\nEvotec is a life science company that is pioneering the future of drug\ndiscovery and development. By integrating breakthrough science with AI-driven\ninnovation and advanced technologies, we accelerate the journey from concept\nto cure — faster, smarter, and with greater precision. Our expertise spans\nsmall molecules, biologics, cell therapies and associated modalities,\nsupported by proprietary platforms such as Molecular Patient Databases,\nPanOmics and iPSC-based disease modeling. With flexible partnering models\ntailored to our customers' needs, we work with all Top 20 Pharma companies,\nover 800 biotechs, academic institutions, and healthcare stakeholders. Our\nofferings range from standalone services to fully integrated R&D programs\nand long-term strategic partnerships, combining scientific excellence with\noperational agility. Through Just – Evotec Biologics, we redefine biologics\ndevelopment and manufacturing to improve accessibility and affordability. With\na strong portfolio of over 100 proprietary R&D assets, most of them being\nco-owned, we focus on key therapeutic areas including oncology, cardiovascular\nand metabolic diseases, neurology, and immunology. Evotec's global team of\naround 4,500 experts operates from sites in Europe and the U.S., offering\ncomplementary technologies and services as synergistic centers of excellence.\nLearn more at www.evotec.com (http://www.evotec.com/) and follow us\non LinkedIn (https://www.linkedin.com/company/evotec) and X/Twitter @Evotec\n(https://twitter.com/evotec) .\n\nForward-looking statements\n\nThis announcement contains forward-looking statements concerning future\nevents, including the proposed offering and listing of Evotec's securities.\nWords such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"should,\" \"target,\" \"would\" and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. Such statements include comments regarding\nEvotec's expectations for revenues, Group EBITDA and unpartnered R&D\nexpenses. These forward-looking statements are based on the information\navailable to, and the expectations and assumptions deemed reasonable by Evotec\nat the time these statements were made. No assurance can be given that such\nexpectations will prove to have been correct. These statements involve known\nand unknown risks and are based upon a number of assumptions and estimates,\nwhich are inherently subject to significant uncertainties and contingencies,\nmany of which are beyond the control of Evotec. Evotec expressly disclaims any\nobligations or undertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in Evotec's\nexpectations with respect thereto or any change in events, conditions or\ncircumstances on which any statement is based.\n\nInvestor Relations and Media Contact\n\nDr. Sarah Fakih\nEVP Head of Global Communications & Investor Relations\nSarah.Fakih@evotec.com (mailto:Sarah.Fakih@evotec.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html\n(https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html)\n\nSOURCE Evotec SE\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2lHSTwa-20261015","title":"Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board","author":"PR Newswire","ticker":"EVO","created":"2026-10-15T06:05:07.337Z","tickers":["EVO","EVTG"],"exchange":"NASDAQ","article_body":"Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board\nPR Newswire\n\nHAMBURG, Germany, Oct. 15, 2026\n\n * Will lead Evotec's global scientific strategy and drive differentiation across\nits discovery and development services, technology platforms and proprietary\ninnovation\n * Brings more than 25 years of global experience in pharma, biotechnology and\nacademia\nHAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO)\n(Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna\nHolbrook as Chief Scientific Officer and Member of the Management Board,\neffective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years\nof experience as both a scientist and R&D leader, applying novel\ntechnologies and data approaches to the challenges of drug discovery and\nadvancing programs toward the clinic. Her experience spans multi-modal 'omics,\ndata science, novel therapeutic modalities and precision medicine,\ncomplemented by experience in commercializing innovative technologies, shaping\ndrug discovery partnerships and leading therapeutic research portfolios. At\nEvotec, Dr. Holbrook will draw on recent scientific advances to help customers\nand partners discover and develop new medicines faster and with a higher\nprobability of success.\n\nDr. Christian Wojczewski, Chief Executive Officer of Evotec, said:\n\n\"Joanna has a keen understanding of how data, AI and new technologies are\ntransforming drug discovery and development today. She combines this\nforward-looking perspective with deep scientific expertise and a strong focus\non generating robust, actionable results. I look forward to working with her\nas we continue to strengthen Evotec's position as a leading partner for any\norganization that strives to bring new, groundbreaking medicines to market.\"\n\nDr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal\nand Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk.\nPrior to that she held positions at UK biotech companies Biomodal, where she\nserved as Chief Scientific Officer, and BenevolentAI, where she was Vice\nPresident, Translational Medicine. She was also Professor of Bioinformatics at\nthe University of Southampton and Senior Principal Investigator at the\nSingapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at\nNational University of Singapore. She started her career at GSK, where she\nheld positions of increasing responsibility across therapy areas and\nbioinformatics. She holds a Ph.D. in Molecular Cell Biology from University\nCollege London and a B.Sc. in Genetics from the University of Newcastle.\n\nDr. Joanna Holbrook, Evotec's incoming Chief Scientific Officer, added:\n\n\"Evotec has exceptional breadth of scientific expertise and capabilities\nspanning drug discovery, drug development and manufacturing. I am excited by\nthe opportunity to work across the business to strengthen our scientific\ndifferentiation, build integrated solutions to the most important challenges\nin drug discovery, and develop new capabilities that are unique to Evotec.\"\n\nAbout Evotec SE\n\nEvotec is a life science company that is pioneering the future of drug\ndiscovery and development. By integrating breakthrough science with AI-driven\ninnovation and advanced technologies, we accelerate the journey from concept\nto cure — faster, smarter, and with greater precision. Our expertise spans\nsmall molecules, biologics, cell therapies and associated modalities,\nsupported by proprietary platforms such as Molecular Patient Databases,\nPanOmics and iPSC-based disease modeling. With flexible partnering models\ntailored to our customers' needs, we work with all Top 20 Pharma companies,\nover 800 biotechs, academic institutions, and healthcare stakeholders. Our\nofferings range from standalone services to fully integrated R&D programs\nand long-term strategic partnerships, combining scientific excellence with\noperational agility. Through Just – Evotec Biologics, we redefine biologics\ndevelopment and manufacturing to improve accessibility and affordability. With\na strong portfolio of over 100 proprietary R&D assets, most of them being\nco-owned, we focus on key therapeutic areas including oncology, cardiovascular\nand metabolic diseases, neurology, and immunology. Evotec's global team of\naround 4,500 experts operates from sites in Europe and the U.S., offering\ncomplementary technologies and services as synergistic centers of excellence.\nLearn more at www.evotec.com (http://www.evotec.com/) and follow us\non LinkedIn (https://www.linkedin.com/company/evotec) and X/Twitter @Evotec\n(https://twitter.com/evotec) .\n\nForward-looking statements\n\nThis announcement contains forward-looking statements concerning future\nevents, including the proposed offering and listing of Evotec's securities.\nWords such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"should,\" \"target,\" \"would\" and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. Such statements include comments regarding\nEvotec's expectations for revenues, Group EBITDA and unpartnered R&D\nexpenses. These forward-looking statements are based on the information\navailable to, and the expectations and assumptions deemed reasonable by Evotec\nat the time these statements were made. No assurance can be given that such\nexpectations will prove to have been correct. These statements involve known\nand unknown risks and are based upon a number of assumptions and estimates,\nwhich are inherently subject to significant uncertainties and contingencies,\nmany of which are beyond the control of Evotec. Evotec expressly disclaims any\nobligations or undertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in Evotec's\nexpectations with respect thereto or any change in events, conditions or\ncircumstances on which any statement is based.\n\nInvestor Relations and Media Contact\n\nDr. Sarah Fakih\nEVP Head of Global Communications & Investor Relations\nSarah.Fakih@evotec.com (mailto:Sarah.Fakih@evotec.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html\n(https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html)\n\nSOURCE Evotec SE\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T06:05:07.383624847Z","server_sent_at_ms":1792044307383},"received_at":"2026-10-15T06:05:07.434Z","source_url":"https://www.prnewswire.com/news-releases/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-member-of-the-management-board-302909597.html"},"analysis":{"id":"157998","press_release_id":"169776","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Evotec SE appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board, effective November 1, 2026.\n\nHolbrook brings 25+ years of R&D leadership, most recently as Therapy Area Head for cardiovascular, renal and hepatic disease at Novo Nordisk, with prior roles at Biomodal, BenevolentAI and GSK.\n\nShe will lead Evotec's global scientific strategy across discovery and development services, technology platforms and proprietary innovation — a leadership upgrade, but not a disruptive executive departure.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Big-pharma-schooled CSO hire reinforces Evotec's AI/data-driven drug discovery positioning."},"keyFigures":{"customDimensions":{"effective_date":"November 1, 2026"}},"quotedText":"Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today.","namedEntities":{"people":[{"name":"Dr. Joanna Holbrook","role":"incoming Chief Scientific Officer, Evotec"},{"name":"Dr. Christian Wojczewski","role":"CEO, Evotec"},{"name":"Dr. Sarah Fakih","role":"EVP Head of Global Communications & Investor Relations, Evotec"}],"products":["Molecular Patient Databases","PanOmics","Just – Evotec Biologics"],"companies":[{"name":"Evotec SE","ticker":"EVO","relationship":"filer"},{"name":"Novo Nordisk","relationship":"Holbrook's prior employer"},{"name":"Biomodal","relationship":"Holbrook's prior employer (CSO)"},{"name":"BenevolentAI","relationship":"Holbrook's prior employer"},{"name":"GSK","relationship":"Holbrook's early-career employer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"C-suite appointment (CSO + management board seat) at a mid-cap life science company, but it is not a CEO departure or sudden vacancy; it is a planned hire with a clear start date and strong credentials. Routine corporate-governance news."},"tickerRelevance":{"others":[{"ticker":"EVT","relevance":"Frankfurt Prime Standard listing of Evotec SE"}],"primary":"EVO"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":["board_change"],"importanceComponents":{"tickerTier":"mid-cap biotech services","eventGravity":"planned C-suite appointment, no vacancy/sudden departure","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"executive_change","event_type_secondary":["board_change"],"sentiment":"bullish","material_impact_score":2,"narrative":"Evotec SE appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board, effective November 1, 2026.\n\nHolbrook brings 25+ years of R&D leadership, most recently as Therapy Area Head for cardiovascular, renal and hepatic disease at Novo Nordisk, with prior roles at Biomodal, BenevolentAI and GSK.\n\nShe will lead Evotec's global scientific strategy across discovery and development services, technology platforms and proprietary innovation — a leadership upgrade, but not a disruptive executive departure.","key_figures":{"customDimensions":{"effective_date":"November 1, 2026"}},"named_entities":{"people":[{"name":"Dr. Joanna Holbrook","role":"incoming Chief Scientific Officer, Evotec"},{"name":"Dr. Christian Wojczewski","role":"CEO, Evotec"},{"name":"Dr. Sarah Fakih","role":"EVP Head of Global Communications & Investor Relations, Evotec"}],"products":["Molecular Patient Databases","PanOmics","Just – Evotec Biologics"],"companies":[{"name":"Evotec SE","ticker":"EVO","relationship":"filer"},{"name":"Novo Nordisk","relationship":"Holbrook's prior employer"},{"name":"Biomodal","relationship":"Holbrook's prior employer (CSO)"},{"name":"BenevolentAI","relationship":"Holbrook's prior employer"},{"name":"GSK","relationship":"Holbrook's early-career employer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T06:05:13.036Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap biotech services","eventGravity":"planned C-suite appointment, no vacancy/sudden departure","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":5583,"modelName":"glm-5.3-flashx"}}